[HTML][HTML] Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study
Abstract Background Tocilizumab is an IgG1 class recombinant humanized monoclonal
antibody that directly inhibits the IL-6 receptor. Several randomized clinical trials have …
antibody that directly inhibits the IL-6 receptor. Several randomized clinical trials have …
[HTML][HTML] Tocilizumab Outcomes in Critically Ill COVID-19 Patients Admitted to the ICU and the Role of Non-Tocilizumab COVID-19-Specific Medical Therapeutics
Background: Tocilizumab is a monoclonal antibody proposed to manage cytokine release
syndrome (CRS) associated with severe COVID-19. Previously published reports have …
syndrome (CRS) associated with severe COVID-19. Previously published reports have …
[HTML][HTML] Tocilizumab exerts anti-inflammatory activity in six critically ill COVID-19 patients: a retrospective analysis
S Qian, J An, F Qi, L Ye, Q Chen, X Liu… - Annals of Translational …, 2020 - ncbi.nlm.nih.gov
Background Coronavirus disease 2019 (COVID-19) has become a worldwide pandemic,
affecting countries across the globe. With no current vaccine, treatment is still a critical …
affecting countries across the globe. With no current vaccine, treatment is still a critical …
[HTML][HTML] Association between tocilizumab treatment of hyperinflammatory patients with COVID-19 in a critical care setting and elevated incidence of hospital-acquired …
B Minihan, E McAuliffe, J Powell, SL Wong… - Journal of Hospital …, 2022 - Elsevier
Background Tocilizumab is an interleukin-6 inhibitor that reduces mortality and the need for
invasive mechanical ventilation, while increasing the possibility of successful hospital …
invasive mechanical ventilation, while increasing the possibility of successful hospital …
[HTML][HTML] Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update
IM Tleyjeh, Z Kashour, M Riaz, L Hassett… - Clinical Microbiology …, 2021 - Elsevier
Objectives Cytokine release syndrome with elevated interleukin-6 (IL-6) levels is associated
with multiorgan damage and death in severe coronavirus disease 2019 (COVID-19). Our …
with multiorgan damage and death in severe coronavirus disease 2019 (COVID-19). Our …
Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis
R Rossotti, G Travi, N Ughi, M Corradin, C Baiguera… - Journal of Infection, 2020 - Elsevier
Background As the novel SARS-CoV-2 pandemic occurred, no specific treatment was yet
available. Inflammatory response secondary to viral infection might be the driver of severe …
available. Inflammatory response secondary to viral infection might be the driver of severe …
[HTML][HTML] Impact of tocilizumab administration on mortality in severe COVID-19
A Tsai, O Diawara, RG Nahass, L Brunetti - Scientific reports, 2020 - nature.com
The novel coronavirus disease 2019 (COVID-19) worldwide pandemic has placed a
significant burden on hospitals and healthcare providers. The immune response to this …
significant burden on hospitals and healthcare providers. The immune response to this …
[HTML][HTML] Effects of Tocilizumab in COVID-19 patients: a cohort study
CA Vu, KJ DeRonde, AD Vega, M Maxam, G Holt… - BMC infectious …, 2020 - Springer
Background Due to the lack of proven therapies, we evaluated the effects of early
administration of tocilizumab for COVID-19. By inhibition of the IL-6 receptor, tocilizumab …
administration of tocilizumab for COVID-19. By inhibition of the IL-6 receptor, tocilizumab …
Tocilizumab in the management of COVID-19: a preliminary report
M Li, EJ Yoo, M Baram, M McArthur, C Skeehan… - The American Journal of …, 2021 - Elsevier
Importance Pneumonia due to COVID-19 can lead to respiratory failure and death due to the
development of the acute respiratory distress syndrome. Tocilizumab, a monoclonal …
development of the acute respiratory distress syndrome. Tocilizumab, a monoclonal …
[HTML][HTML] Tocilizumab treatment in critically ill patients with COVID-19: A retrospective observational study
E Huang, S Isonaka, H Yang, E Salce… - International Journal of …, 2021 - Elsevier
Objective Elevated levels of pro-inflammatory cytokines are observed in severe COVID-19
infections, and cytokine storm is associated with disease severity. Tocilizumab, an …
infections, and cytokine storm is associated with disease severity. Tocilizumab, an …